Skip to main content
SpringerLink
Log in

Preclinical Results with If Current Inhibition by Ivabradine

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Ivabradine, a highly selective If current inhibitor acting directly on the sinoatrial node, induces a rapid, sustained and dose-dependent reduction of heart rate at rest and during exercise, without significant effects on atrioventricular conduction, left ventricular (LV) contraction-relaxation or vascular tissues. These properties, associated with an improvement in LV loading related to bradycardia, resulted in an increase in stroke volume and preservation of cardiac output at rest and during exercise. Reducing myocardial oxygen consumption and improving oxygen supply, ivabradine reduced the severity of ischaemia and associated regional contractile dysfunction of the stunned myocardium. Long-term administration of ivabradine in rats with chronic heart failure improved cardiac haemodynamics associated with a progressive remodelling of LV structure. In dyslipidaemic mice, ivabradine prevented the renal and cerebrovascular endothelial dysfunction associated with atherosclerosis. These preclinical data suggest that long-term reduction in heart rate with ivabradine might interact with multiple a priori unexpected mechanisms involved in cardiac and vascular remodelling processes associated with chronic heart diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Vilaine JP, Thollon C, Villeneuve N, et al. Procoralan, a new selective If current inhibitor. Eur Heart J 2003; 5: G26–35

    Article  CAS  Google Scholar 

  2. Thollon C, Cambarrat C, Vian J, et al. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol 1994; 112: 3–42

    Article  Google Scholar 

  3. Thollon C, Bidouard JP, Cambarrat C, et al. Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257. Eur J Pharmacol 1997; 339: 43–51

    Article  PubMed  CAS  Google Scholar 

  4. Bois P, Bescond J, Renaudon B, et al. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoa-trial node cells. Br J Pharmacol 1996; 118: 1051–7

    Article  PubMed  CAS  Google Scholar 

  5. Thollon C, Bedut S, Villeuneuve N, et al. Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity. Br J Pharmacol 2007; 150: 37–46

    Article  PubMed  CAS  Google Scholar 

  6. Milanesi R, Baruscotti M, Gnecchi-Ruscone T, et al. Familial sinus bradycardia associated with a mutation in the cardiac pacemaker channel. N Engl J Med 2006; 354: 151–7

    Article  PubMed  CAS  Google Scholar 

  7. Simon L, Ghaleh B, Puybasset L, et al. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 1995; 275: 659–66

    PubMed  CAS  Google Scholar 

  8. Borer JS, Fox K, Jaillon P, et al. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicenter, placebo-controlled trial. Circulation 2003; 107: 817–23

    Article  PubMed  Google Scholar 

  9. Vilaine JP, Bidouard JP, Lesage L, et al. Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent in exercise-induced myocardial ischemia in pigs. J Cardiovasc Pharmacol 2003; 42: 688–96

    Article  PubMed  CAS  Google Scholar 

  10. Colin P, Ghaleh B, Hittinger L, et al. Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise. Am J Physiol Circ Physiol 2002; 282: H672–9

    CAS  Google Scholar 

  11. Mulder P, Barbier S, Chagraoui A, et al. Long-term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004; 109: 1674–9

    Article  PubMed  CAS  Google Scholar 

  12. Mulder P, Thuillez C. Heart rate slowing for myocardial dysfunction/heart failure: rationale and preclinical studies. In: Camm J, Tandera M, editors. Heart rate slowing by If current inhibition. Advances in Cardiology. Vol. 43. Basel: Karger, 2006: 97–105

    Google Scholar 

  13. Colin P, Ghaleh B, Monnet X, et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Circ Physiol 2003; 284: H676–82

    CAS  Google Scholar 

  14. Colin P, Ghaleh B, Monnet X, et al. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J Pharmacol Exp Ther 2004; 308: 236–40

    Article  PubMed  CAS  Google Scholar 

  15. Berdeaux A, Drieu La Rochelle C, Richard V, et al. Opposed responses of large and small coronary arteries to propranolol during exercise in dogs. Am J Physiol 1991; 261: H265–70

    PubMed  CAS  Google Scholar 

  16. Drieu La Rochelle C, Giudicelli JF, Berdeaux A. Differential effects of celiprolol and atenolol on large epicardial coronary arteries in conscious dogs at rest and during exercise. J Cardiovasc Pharmacol 1993; 22: 15–21

    Article  Google Scholar 

  17. Vigué B, Ghaleh B, Giudicelli JF. α1- and α2-Adrenergic control of large and small coronary arteries during exercise in conscious dogs under β-blockade. Fund Clin Pharmacol 1993; 7: 520–7

    Article  Google Scholar 

  18. Monnet X, Ghaleh B, Colin P, et al. Effect of heart reduction with ivabradine on exercise-induced myocardial ischemia and stunning. J Pharmacol Exp Ther 2001; 299: 1133–9

    PubMed  CAS  Google Scholar 

  19. Bache RJ, Cobb FR. Effect of maximal coronary vasodilation on transmural myocardial perfusion during tachycardia in the awake dog. Circ Res 1977; 41: 648–53

    Article  PubMed  CAS  Google Scholar 

  20. Ferro G, Duilio C, Spinelli L, et al. Relation between diastolic perfusion time and coronary artery stenosis during stress-induced myocardial ischemia. Circulation 1995; 92: 342–7

    Article  PubMed  CAS  Google Scholar 

  21. Monnet X, Colin P, Ghaleh B, et al. Heart rate reduction during exercise-induced myocardial ischaemia and stunning. Eur Heart J 2004; 25: 579–86

    Article  PubMed  Google Scholar 

  22. Ferrari R, Cargnoni A, Ceconi C. Anti-ischemic effect of ivabradine. Pharmacol Res 2006; 53: 435–9

    Article  PubMed  CAS  Google Scholar 

  23. Tardif JC, Ford I, Tendera M, et al. Effect of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529–36

    Article  PubMed  CAS  Google Scholar 

  24. Lucats L, Ghaleh B, Colin P, et al. Heart rate reduction by inhibition of If or by β-blockade has different effects on postsystolic wall thickening. Br J Pharmacol 2007; 150: 335–41

    Article  PubMed  CAS  Google Scholar 

  25. Lucats L, Ghaleh B, Monnet X, et al. Conversion of post-systolic wall thickening into ejectional thickening by selective heart rate reduction during myocardial stunning. Eur Heart J 2007; 28: 872–9

    Article  PubMed  Google Scholar 

  26. Lei L, Zhou R, Zheng W, et al. Bradycardia induces angio-genesis, increases coronary reserve, and preserves function of the postinfarcted heart. Circulation 2004; 110: 796–802

    Article  PubMed  Google Scholar 

  27. Zheng W, Brown MD, Brock TA, et al. Bradycardia-induced coronary angiogenesis is dependent on vascular growth factor. Circ Res 1999; 85: 192–8

    Article  PubMed  CAS  Google Scholar 

  28. Langenbach MR, Schmitz-Spanke S, Brockert M, et al. Comparison of a β-blocker and an If current inhibitor in rabbits with myocardial infarction. J Cardiovasc Surg 2006; 47: 719–25

    CAS  Google Scholar 

  29. Thorin E, Drouin A, Gendro M-E, et al. Chronic heart rate reduction by ivabradine prevents cerebrovascular dysfunction in dyslipidemic mice [abstract; in French]. Arch Mal Coeur Vaisseaux 2007; 100(II): 653

    Google Scholar 

  30. Gendron ME, Drouin A, Thorin E, et al. Chronic heart rate reduction by the selective If current inhibitor ivabradine prevents endothelial dysfunction of renal arteries in dyslipidemic mice [abstract; in French]. Arch Mal Coeur Vaisseaux 2007; 100(II): 897

    Google Scholar 

  31. Vilaine JP. The discovery of the selective I(f) current inhibitor ivabradine: a new therapeutic approach to ischemic heart disease. Pharmacol Res 2006; 53: 424–34

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The author received financial support from the Institut de Recherche International Servier for the preparation of this manuscript.

Author information

Authors and Affiliations

  1. INSERM U 841, Pharmacology Laboratory, Créteil Faculty of Medicine & Paris XII University, 8, rue du Général Sarrail, 94010, Créteil, France

    Alain Berdeaux

Authors
  1. Alain Berdeaux
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alain Berdeaux.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berdeaux, A. Preclinical Results with If Current Inhibition by Ivabradine. Drugs 67 (Suppl 2), 25–33 (2007). https://doi.org/10.2165/00003495-200767002-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767002-00004

Keywords

Search

Navigation